• Explore /
  • Poster
  • / A multicenter, randomized, double-blind, placebo-controlled phase III study of anlotinib or placebo in combination with gemcitabine and cisplatin (GP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC).

A multicenter, randomized, double-blind, placebo-controlled phase III study of anlotinib or placebo in combination with gemcitabine and cisplatin (GP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC).

Abstract Poster

Authors

null

Yunpeng Yang

State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-sen University Cancer Center, Guangzhou, China

Yunpeng Yang , Yan Huang , Wenfeng Fang , Yuxiang Ma , Qingqing Cai , Zhi-Ming Li , Hongyun Zhao , Yuanyuan Zhao , Ting Zhou , Shaodong Hong , Yaxiong Zhang , Li Zhang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03601975

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS6089)

DOI

10.1200/JCO.2019.37.15_suppl.TPS6089

Abstract #

TPS6089

Poster Bd #

78a

Abstract Disclosures

Similar Posters

First Author: Hai-Qiang Mai

First Author: Jennifer J. Knox

First Author: Ashwin Reddy Sama

First Author: Inkeun Park